- Home
- DSGN vs RIGL Comparison
DSGN vs RIGL Comparison
Compare DSGN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGN | RIGL |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 628.4M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DSGN | RIGL |
|---|---|---|
| Price | $10.74 | $26.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $15.25 | ★ $45.67 |
| AVG Volume (30 Days) | 245.5K | ★ 360.8K |
| Earning Date | 03-09-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $1.34 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $2.62 | $15.50 |
| 52 Week High | $11.23 | $52.24 |
Technical Indicators
Market Signals| Indicator | DSGN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 33.69 |
| Support Level | $9.64 | $26.38 |
| Resistance Level | $11.18 | $30.59 |
| Average True Range (ATR) | 0.57 | 1.03 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 67.86 | 37.27 |
Price Performance
Historical ComparisonAbout DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.